{"prompt": "[\"defined by Hy's law). Therefore, investigators must report as an adverse event the\", 'occurrence of either of the following:', 'Treatment-emergent ALT or AST > 3 X baseline value in combination with total', 'bilirubin > 2 X ULN (of which 35% is direct bilirubin)', 'Treatment-emergent ALT or AST > 3 X baseline value in combination with clinical', 'jaundice.', 'The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal', 'laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.2) and', 'reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event),', 'either as a serious adverse event or an adverse event of special interest (see Section 5.4.2).', '5.3.5.8', 'Deaths', 'All deaths that occur during the protocol-specified adverse event reporting period (see', 'Section 5.3.1), regardless of relationship to emicizumab, must be recorded on the Adverse', 'Event eCRF and immediately reported to the Sponsor (see Section 5.4.2). This includes', 'death attributed to progression of hemophilia A.', 'Death should be considered an outcome and not a distinct event. The event or condition that', 'caused or contributed to the fatal outcome should be recorded as the single medical concept', 'on the Adverse Event eCRF. Generally, only one such event should be reported. If the', 'cause of death is unknown and cannot be ascertained at the time of reporting,', '\"unexplained death\" should be recorded on the Adverse Event eCRF. If the cause of death', 'later becomes available (e.g., after autopsy), \"unexplained death\" should be replaced by the', 'established cause of death. The term \"sudden death\" should not be used unless combined', 'with the presumed cause of death (e.g., \"sudden cardiac death\").', 'If the death is attributed to progression of hemophilia A, \"hemophilia A progression\" should', 'be recorded on the Adverse Event eCRF.', 'Deaths that occur after the adverse event reporting period should be reported as described', 'in Section 5.6.', '5.3.5.9', 'Pre-existing Medical Conditions', 'A pre-existing medical condition is one that is present during the study Screening Period. Such', 'conditions should be recorded on the General Medical History and Baseline Conditions', 'eCRF.', 'A pre-existing medical condition should be recorded as an adverse event only if the', 'frequency, severity, or character of the condition worsens during the study. When recording', 'such events on the Adverse Event eCRF, it is important to convey the concept that the pre-', 'existing condition has changed by including applicable descriptors (e.g., \"more frequent', 'headaches\").', '5.3.5.10', 'Lack of Efficacy or Worsening of Hemophilia A', 'Medical occurrences or symptoms of deterioration that are anticipated as part of hemophilia', 'A should be recorded as an adverse event if judged by the investigator to have unexpectedly', 'worsened in severity or frequency or changed in nature at any time during the study. When', 'Emicizumab - F. Hoffmann-La Roche Ltd', '137 / Protocol MO39129, Version 3']['recording an unanticipated worsening of hemophilia A on the Adverse Event eCRF, it is', 'important to convey the concept that the condition has changed by including applicable', 'descriptors (e.g., \"accelerated hemophilia A\").', '5.3.5.11', 'Hospitalization or Prolonged Hospitalization', 'Any adverse event that results in hospitalization (i.e., inpatient admission to a hospital) or', 'prolonged hospitalization should be documented and reported as a serious adverse event', '(per the definition of serious adverse event in Section 5.2.2), except as outlined below.', 'An event that leads to hospitalization under the following circumstances should not be', 'reported as an adverse event or a serious adverse event:', 'Hospitalization for respite care', 'Planned hospitalization required by the protocol (e.g., for study drug administration)', 'Hospitalization for a pre-existing condition, provided that all of the following criteria are', 'met:', 'The hospitalization was planned prior to the study or was scheduled during the study', 'when elective surgery became necessary because of the expected normal', 'progression of the disease', 'The patient has not experienced an adverse event.', 'The following hospitalization scenarios are not considered to be serious adverse events, but', 'should be reported as adverse events instead:', 'Hospitalization that was necessary because of patient requirement for outpatient care', 'outside of normal outpatient clinic operating hours.', '5.3.5.12', 'Adverse Events Associated with an Overdose or Error in Drug', 'Administration', 'An overdose is the accidental or intentional use of a drug in an amount higher than the dose', 'being studied. An overdose or incorrect administration of study treatment is not itself an', 'adverse event, but it may result in an adverse event. All adverse events associated with an', 'overdose or incorrect administration of emicizumab should be recorded on the Adverse Event', 'eCRF. If the associated adverse event fulfills seriousness criteria, the event should be', 'reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event;', 'see Section 5.4.2).', 'No information about overdose is currently available. Accidental overdose may result in', 'enhanced procoagulant effects of emicizumab. As with any medication overdose, patients', 'may be more susceptible to both known and unknown risks and should be closely monitored', 'as appropriate by the investigator.', '5.3.5.13', 'Patient-Reported Outcome Data', 'The PRO measurements are described in Section 4.5.8. The methods for collecting and', 'analyzing PRO data are different from those used for observed or volunteered adverse', 'events. Owing to these differences, PRO data will not be reported as adverse events and no', 'attempt will be made to resolve any noticeable discrepancies between PRO data and', 'observed or volunteered adverse events. All adverse events will be reported by the', 'Emicizumab - F. Hoffmann-La Roche Ltd', '138 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}